HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry - PubMed (original) (raw)
HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry
K Park et al. Histopathology. 2006 May.
Abstract
Aim: To determine the HER2 status of ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) of the breast. The increased prevalence of HER2 amplification and overexpression in DCIS is considered to be maintained in the intraductal component of IDC; however, HER2 amplification and overexpression are detected much less in IDC.
Methods and results: Fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) were performed to detect HER2 in 270 IDCs with an intraductal component and in 50 pure DCIS samples; IHC was also performed in 116 metastatic nodes. HER2 was found to be amplified in 77 cases (28.5%) and overexpressed in 79 (29.3%) of the 270 IDCs. HER2 amplification was similar between intraductal and invasive components of the same tumour. The concordance for HER2 status between invasive and intraductal components of individual tumours was 98.5% and 99.3% by FISH and IHC, respectively. HER2 was amplified in 25 (50%) of the 50 pure DCIS samples. HER2 overexpression in metastatic nodes resembled the HER2 status in the primary tumour for 108 (93.1%) of 116 cases (kappa =0.831).
Conclusion: Our study indicates that the intraductal component of IDC may differ biologically when compared with pure DCIS. HER2 appears to lack a critical role in the progression from DCIS to IDC and HER2 status is maintained in metastatic lesions.
Similar articles
- The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK, Tjan S, Parkes RK, O'Malley FP. Latta EK, et al. Mod Pathol. 2002 Dec;15(12):1318-25. doi: 10.1097/01.MP.0000038462.62634.B1. Mod Pathol. 2002. PMID: 12481013 - Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a calibrated aCGH study.
Iakovlev VV, Arneson NC, Wong V, Wang C, Leung S, Iakovleva G, Warren K, Pintilie M, Done SJ. Iakovlev VV, et al. Clin Cancer Res. 2008 Jul 15;14(14):4446-54. doi: 10.1158/1078-0432.CCR-07-4960. Clin Cancer Res. 2008. PMID: 18628458 - HER2 as a prognostic factor in breast cancer.
Ménard S, Fortis S, Castiglioni F, Agresti R, Balsari A. Ménard S, et al. Oncology. 2001;61 Suppl 2:67-72. doi: 10.1159/000055404. Oncology. 2001. PMID: 11694790 Review.
Cited by
- Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis.
Ploumen RAW, Claassens EL, Kooreman LFS, Keymeulen KBMI, van Kats MACE, Gommers S, Siesling S, van Nijnatten TJA, Smidt ML. Ploumen RAW, et al. Breast Cancer Res Treat. 2023 Sep;201(2):227-235. doi: 10.1007/s10549-023-07012-z. Epub 2023 Jul 3. Breast Cancer Res Treat. 2023. PMID: 37395816 Free PMC article. - Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer.
Najjar MK, Manore SG, Regua AT, Lo HW. Najjar MK, et al. Genes (Basel). 2022 Nov 8;13(11):2065. doi: 10.3390/genes13112065. Genes (Basel). 2022. PMID: 36360302 Free PMC article. Review. - Advances in Nanotechnology for Cancer Immunoprevention and Immunotherapy: A Review.
Koyande NP, Srivastava R, Padmakumar A, Rengan AK. Koyande NP, et al. Vaccines (Basel). 2022 Oct 16;10(10):1727. doi: 10.3390/vaccines10101727. Vaccines (Basel). 2022. PMID: 36298592 Free PMC article. Review. - The role of HER2 alterations in clinicopathological and molecular characteristics of breast cancer and HER2-targeted therapies: a comprehensive review.
Asgari-Karchekani S, Aryannejad A, Mousavi SA, Shahsavarhaghighi S, Tavangar SM. Asgari-Karchekani S, et al. Med Oncol. 2022 Sep 29;39(12):210. doi: 10.1007/s12032-022-01817-6. Med Oncol. 2022. PMID: 36175719 Review. - Genomic profiling reveals heterogeneous populations of ductal carcinoma in situ of the breast.
Nagasawa S, Kuze Y, Maeda I, Kojima Y, Motoyoshi A, Onishi T, Iwatani T, Yokoe T, Koike J, Chosokabe M, Kubota M, Seino H, Suzuki A, Seki M, Tsuchihara K, Inoue E, Tsugawa K, Ohta T, Suzuki Y. Nagasawa S, et al. Commun Biol. 2021 Apr 1;4(1):438. doi: 10.1038/s42003-021-01959-9. Commun Biol. 2021. PMID: 33795819 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous